Professor, Internal Medicine, Washington University School of Medicine
Nephrology
Dr. Daniel W. Coyne, MD
|
|
Give Review
Daniel Coyne works in the field of Nephrology. He went to Case Western Reserve University School of Medicine. Daniel Coyne is a published doctor. He has 100 papers published. The most current publication "High-flux dialysis lowers plasma leptin concentration in chronic dialysis patients." He accepts all Medicare patients.
Publications
- Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis.
- Evaluating the Safety and Rationale for Cinacalcet Posttransplant Hyperparathyroidism and Hypercalcemia.
- A Randomized Multicenter Trial of Paricalcitol versus Calcitriol for Secondary HyperParathyroidism in Stages 3-4 CKD.
- Update on intravenous iron choices.
- Anemia in Chronic Kidney Disease: Treating the Numbers, Not the Patients.
- The KDOQI US Commentary on KDIGO Anemia Guideline and Quality of Life.
- Effects of paricalcitol on Calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study.
- Is allosensitization a strong enough reason to avoid transfusions?
- Anemia management in dialysis: Why the FDA and CMS have it right (and how KDIGO got it wrong).
- Hepcidin: clinical utility as a diagnostic tool and therapeutic target.
- A crossover intervention trial evaluating the efficacy of a chlorhexidine-impregnated sponge in reducing catheter-related bloodstream infections among patients undergo...
- Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients.
- Anemia management in chronic Kidney disease: intravenous iron steps forward.
- Vitamin D deficiency and anemia in early chronic Kidney disease.
- It's time to compare anemia management strategies in hemodialysis.
- Seeking safe and efficacious anemia management.
- Posttransplant anemia: the role of sirolimus.
- Variability of ferritin measurements in chronic Kidney disease; implications for iron management.
- Managing anemia in for-profit dialysis chains: when ethics and business conflict.
- Ferric gluconate treatment provides cost savings in patients With high ferritin and low transferrin saturation.
- Introduction to "A road map for intravenous iron and anemia management: preparing for the future".
- A comprehensive vision for intravenous iron therapy.
- Results of an anemia management program to reduce high epoetin doses by targeted use of i.v. ferric gluconate.
- The TREAT study answers a question, not the question.
- A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of Phosphorus in hemodialysis patients.
- Thrombosis With erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role?
- High-molecular weight iron dextran: a wolf in sheep's clothing?
- From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy.
- Relative mortality and epoetin alpha dose among hemodialysis patients.
- Ferric gluconate reduces epoetin requirements in hemodialysis patients With elevated ferritin.
- Management of secondary hyperparathyroidism in stages 3 and 4 chronic Kidney disease.
- Use of erythropoiesis-stimulating agents in patients with anemia of chronic Kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing...
- Use of epoetin in chronic renal Failure.
- Practice recommendations based on low, very low, and missing evidence.
- Influence of industry on Renal guideline development.
- Anemia in the Kidney-transplant patient.
- Cinacalcet for secondary hyperParathyroidism in patients receiving hemodialysis.
- Ability of non-high-density lipoprotein cholesterol and calculated intermediate-density lipoprotein to identify nontraditional lipoprotein subclass risk factors in dia...
- Prevalence, treatment, and control of hypertension in Chronic hemodialysis patients in the United States.
- Differential effects of Acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients.
- Parenteral iron safety and the special article "Just the FAQs: frequently asked questions about iron and anemia in patients with chronic Kidney disease".
- Variation in plasma leptin concentrations after unilateral nephrectomy.
- Iron supplementation to treat anemia in patients with chronic Kidney disease.
- The effect of oral niacinamide on plasma Phosphorus levels in peritoneal dialysis patients.
- Ferumoxytol for treatment of iron deficiency anemia in patients with chronic Kidney disease.
- Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients.
- Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic Kidney disease.
- Iron deficiency anemia and iron losses after Renal transplantation.
- Conflicts of interest and viewpoint bias in KDOQI and KDIGO workgroups.
- Comment on "Does ferric gluconate lower epoetin requirements in hemodialysis patients With high ferritin levels?".
- C.E.R.A. maintains stable control of hemoglobin in patients with chronic Kidney disease on dialysis when administered once every two weeks.
- ACE inhibitor-based, directly observed therapy for Hypertension in hemodialysis patients.
- Labile iron in parenteral iron formulations: a quantitative and comparative study.
- The spectrum of infection-related morbidity in hospitalized haemodialysis patients.
- Vitamin D analogs: new therapeutic agents for secondary hyperParathyroidism.
- Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety.
- Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
- Oral feeding Acutely down-regulates serum PTH in hemodialysis patients.
- Drug insight: Safety of intravenous iron supplementation With sodium ferric gluconate complex.
- Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients.
- Ferric gluconate is highly efficacious in anemic hemodialysis patients With high serum ferritin and low transferrin saturation: results of the Dialysis Patients'' Resp...
- Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients.
- Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration.
- Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study.
- Vitamin D and outcomes in chronic Kidney disease.
- Beauveria bassiana (Balsamo) Vuillemin as an endophyte in tissue culture banana (Musa spp.).
- A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperParathyroidism in CKD stages 3 and 4.
- Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic Kidney disease.
- Vitamin D receptor activator selectivity in the treatment of secondary hyperParathyroidism: understanding the differences among therapies.
- Paricalcitol capsule for the treatment of secondary hyperParathyroidism in stages 3 and 4 CKD.
- Screenhouse and field persistence of nonpathogenic endophytic Fusarium oxysporum in Musa tissue culture plants.
- Oral paricalcitol for the treatment of secondary hyperparathyroidism in chronic Kidney disease.
- Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.
- Effect of Endophytic Fusarium oxysporum on Host Preference of Radopholus similis to Tissue Culture Banana Plants.
- Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 Diabetes (VITAL study): a randomised controlled trial.
- Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic Kidney disease.
- The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics.
- An assessment of cinacalcet HCl effects on bone histology in dialysis patients With secondary hyperparathyroidism.
- Differential effects of very high doses of doxercalciferol and paricalcitol on serum Phosphorus in hemodialysis patients.
- Predictors of the response to treatment in anemic hemodialysis patients With high serum ferritin and low transferrin saturation.
- Once-weekly intravenous paricalcitol in the treatment of secondary hyperParathyroidism in hemodialysis patients.
- Regulation of mesangial cell cyclooxygenase synthesis by cytokines and glucocorticoids.
- Regulation of eicosanoid biosynthesis by phorbol ester in Madin Darby canine Kidney cells.
- Effect of the tyrosine kinase inhibitor, genistein, on interleukin-1 stimulated PGE2 production in mesangial cells.
- Inhibition of bradykinin-induced increases of cytosolic Ca++ by a novel amiloride analog.
- Bradykinin stimulated PGE2 production is independent of changes in intracellular Calcium in MDCK cells.
- Platelet-derived growth factor A-chain gene transcription is mediated by positive and negative regulatory regions in the promoter.
- Transcriptional control of the platelet-derived growth factor subunit genes.
- Comparison of survival of an expanded polytetrafluoroethylene graft designed for early cannulation to standard wall polytetrafluoroethylene grafts.
- Increased plasma leptin concentration in end-stage renal Disease.
- Upper extremity central venous obstruction in hemodialysis patients: treatment With Wallstents.
- Impaired delivery of hemodialysis prescriptions: an analysis of causes and an approach to evaluation.
- Hyperleptinemia in patients with end-stage renal Disease undergoing continuous ambulatory peritoneal dialysis.
- Hyperleptinaemia of end-stage renal Disease is corrected by renal transplantation.
- High-flux dialysis lowers plasma leptin concentration in Chronic dialysis patients.
- The not-for-profit hospital as a charitable trust: to whom does its value belong?
- Leptin elimination in hyperleptinaemic peritoneal dialysis patients.
- Network 12 Hepatitis B vaccination quality improvement program: an educational program directed at physicians, staff, and patients.
- Intravenous iron: from anathema to standard of care.
Schools
Case Western Reserve University School of Medicine
Emory Affil Hosps
Barnes Jewish Hospital
Procedures Preformed
- Hemodialysis
- Peritoneal Dialysis
Conditions Treated
- Acidosis
- Acute Kidney Failure
- Alkalosis
- Amyloidosis
- View All
Doctors Specialties
- Nephrology
Accepted Insurances
Education
-
Washington University - Barnes-Jewish Hospital -
Emory University -
Case Western Reserve University School of Medicine
Hospital
-
Barnes-Jewish Hospital
Drug Facts
| NPI NUMBER | 1427074749 | |
| NPPES Provider LastName | COYNE | |
| NPPES Provider FirstName | DANIEL | |
| NPPES Provider ZIPCode | 631101032 | |
| NPPES Provider State | MO | |
| Specialty Description | Nephrology | |
| Total Claim Count | 2005.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 0.75 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1427074749 |
| Last Name Of The Provider | COYNE |
| First Name Of The Provider | DANIEL |
| View All |
Similar Doctors
|
|
Dr. Mark D. Ravenscraft, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John Mellas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin J. Martin, MD |
|
|
Dr. David W. Moskowitz, MD |
|
|
Dr. Aubrey R. Morrison, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donovan C. Polack, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Willie R. Ross, MD |
|
|
Dr. Ziyad M. Al Aly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alejandro C. Alvarez, MD |
|
|
Dr. Christian C. Nwankwo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Giselle D. Kohler, MD |
|
|
Dr. Thanh-Mai N. Vo, MD |
|
|
Dr. Esther A. Gonzalez, MD |
|
|
Dr. Jiries S. Dahu, MD |